Michelandrea De Cesare
Overview
Explore the profile of Michelandrea De Cesare including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
958
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El Bezawy R, Percio S, Ciniselli C, De Cesare M, Colella G, Dugo M, et al.
Cancer Gene Ther
. 2022 Mar;
29(10):1394-1404.
PMID: 35352023
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and rapidly lethal tumor, poorly responsive to conventional treatments. In this regards, the identification of molecular alterations underlying DMPM onset and progression...
2.
Colombo D, Gatti L, Sjostrand L, Carenini N, Costantino M, Corna E, et al.
Biochem Pharmacol
. 2022 Jan;
197:114900.
PMID: 34995485
Deubiquitinases (DUBs) mediate the removal of ubiquitin from diverse proteins that participate in the regulation of cell survival, DNA damage repair, apoptosis and drug resistance. Previous studies have shown an...
3.
Sartori A, Corno C, De Cesare M, Scanziani E, Minoli L, Battistini L, et al.
Cancers (Basel)
. 2019 Apr;
11(4).
PMID: 31013908
Ovarian carcinoma, the most lethal gynecological cancer, is characterized by late diagnosis, with drug resistance limiting the efficacy of platinum-based therapy. Since some integrins are upregulated in cancer, including ovarian...
4.
De Cesare M
Anticancer Res
. 2018 Oct;
38(10):5783-5790.
PMID: 30275200
Background/aim: The lipophilic, orally bioavailable camptothecin analogue gimatecan is characterized by improved efficacy over conventional camptothecins on human tumor xenografts. Gimatecan produced excellent outcomes orally with prolonged, low-dose, daily treatments....
5.
Bizarro A, Sousa D, Lima R, Musso L, Cincinelli R, Zuco V, et al.
Molecules
. 2018 Feb;
23(2).
PMID: 29438315
Background: Heat shock protein 90 (HSP90) is a well-known target for cancer therapy. In a previous work, some of us have reported a series of 3-aryl-naphtho[2,3-]isoxazole-4,9-diones as inhibitors of HSP90....
6.
Cassinelli G, Bo L, Favini E, Cominetti D, Pozzi S, Tortoreto M, et al.
Cancer Lett
. 2017 Dec;
415:187-197.
PMID: 29225052
Synovial sarcoma (SS) is an aggressive tumor with propensity for lung metastases which significantly impact patients' prognosis. New therapeutic approaches are needed to improve treatment outcome. Targeting the heparanase/heparan sulfate...
7.
Corno C, Stucchi S, De Cesare M, Carenini N, Stamatakos S, Ciusani E, et al.
Biochem Pharmacol
. 2017 Nov;
147:93-103.
PMID: 29155058
The XPO1/CRM1 inhibitor selinexor (KPT-330), is currently being evaluated in multiple clinical trials as an anticancer agent. XPO1 participates in the nuclear export of FoxO-1, which we previously found to...
8.
Rossini A, Zunino F, Ruggiero G, De Cesare M, Cominetti D, Tortoreto M, et al.
Hematol Oncol
. 2017 Jul;
36(1):360-362.
PMID: 28730742
No abstract available.
9.
Sani M, Lazzari P, Folini M, Spiga M, Zuco V, De Cesare M, et al.
Chemistry
. 2017 Mar;
23(24):5842-5850.
PMID: 28300330
Synthetic tubulysins 24 a-m, containing non-hydrolysable N-substituents on tubuvaline (Tuv), were obtained in high purity and good overall yields using a multistep synthesis. A key step was the formation of...
10.
Ferroni C, Pepe A, Kim Y, Lee S, Guerrini A, Parenti M, et al.
J Med Chem
. 2017 Mar;
60(7):3082-3093.
PMID: 28272894
Prostate cancer (PC) is the fifth leading cause of cancer death in men, and the androgen receptor (AR) represents the primary target for PC treatment, even though the disease frequently...